OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC
Julia Foldi, Adriana Kahn, Andrea Silber, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 17, pp. 3720-3728
Open Access | Times Cited: 13
Julia Foldi, Adriana Kahn, Andrea Silber, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 17, pp. 3720-3728
Open Access | Times Cited: 13
Showing 13 citing articles:
Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC)
Gantumur Battogtokh, Onyinyechi Obidiro, Emmanuel O. Akala
Cancers (2024) Vol. 16, Iss. 11, pp. 2012-2012
Open Access | Times Cited: 4
Gantumur Battogtokh, Onyinyechi Obidiro, Emmanuel O. Akala
Cancers (2024) Vol. 16, Iss. 11, pp. 2012-2012
Open Access | Times Cited: 4
Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure
Thomas Gerald, Solomon L. Woldu, Daniel Halstuch, et al.
Urologic Oncology Seminars and Original Investigations (2025)
Closed Access
Thomas Gerald, Solomon L. Woldu, Daniel Halstuch, et al.
Urologic Oncology Seminars and Original Investigations (2025)
Closed Access
Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer
Alejandro Ríos-Hoyo, Jiawei Dai, Tony Noël, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104494-104494
Closed Access
Alejandro Ríos-Hoyo, Jiawei Dai, Tony Noël, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104494-104494
Closed Access
Development of Multifunctional Targeted Dual-Loaded Polymeric Nanoparticles for Triple-Negative Breast Cancer Treatment
Gantumur Battogtokh, Emmanuel O. Akala
Pharmaceutics (2025) Vol. 17, Iss. 4, pp. 425-425
Open Access
Gantumur Battogtokh, Emmanuel O. Akala
Pharmaceutics (2025) Vol. 17, Iss. 4, pp. 425-425
Open Access
Detrimental impact of chemotherapy dose reduction or discontinuation in early stage triple-negative breast cancer treated with pembrolizumab and neoadjuvant chemotherapy: A multi-center experience
Jayasree Krishnan, Archit Patel, Arya Mariam Roy, et al.
Clinical Breast Cancer (2024) Vol. 24, Iss. 8, pp. e701-e711.e2
Closed Access | Times Cited: 2
Jayasree Krishnan, Archit Patel, Arya Mariam Roy, et al.
Clinical Breast Cancer (2024) Vol. 24, Iss. 8, pp. e701-e711.e2
Closed Access | Times Cited: 2
Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer
Andrew Takchi, Minzhi Zhang, Mohammad Jalalirad, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Andrew Takchi, Minzhi Zhang, Mohammad Jalalirad, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer
Julia Foldi, Kim Blenman, Michał Marczyk, et al.
Breast Cancer Research and Treatment (2024) Vol. 208, Iss. 2, pp. 369-377
Closed Access | Times Cited: 1
Julia Foldi, Kim Blenman, Michał Marczyk, et al.
Breast Cancer Research and Treatment (2024) Vol. 208, Iss. 2, pp. 369-377
Closed Access | Times Cited: 1
Associations of immune checkpoint predictive biomarkers MHC-I and MHC-II with clinical and molecular features in a diverse breast cancer cohort
Xiaopeng Sun, Laura C. Kennedy, Paula I. González-Ericsson, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4077-4081
Closed Access | Times Cited: 1
Xiaopeng Sun, Laura C. Kennedy, Paula I. González-Ericsson, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4077-4081
Closed Access | Times Cited: 1
Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study
Sean R. Miller, Ralph Jiang, Matthew J. Schipper, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 12, pp. 1666-1676
Closed Access | Times Cited: 1
Sean R. Miller, Ralph Jiang, Matthew J. Schipper, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 12, pp. 1666-1676
Closed Access | Times Cited: 1
Immunodiagnosis — the promise of personalized immunotherapy
R. Wang, Kairong Xiong, Zhimin Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
R. Wang, Kairong Xiong, Zhimin Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors
Alfredo V. Chua, Jennifer Delmerico, Haiyang Sheng, et al.
JCO Oncology Practice (2024)
Closed Access
Alfredo V. Chua, Jennifer Delmerico, Haiyang Sheng, et al.
JCO Oncology Practice (2024)
Closed Access
Association of pathological response with long-term survival outcomes after neoadjuvant immunotherapy: A meta-analysis
Chenyu Wei, Haolin Sun, Jiexuan Hu, et al.
International Immunopharmacology (2024) Vol. 133, pp. 112078-112078
Closed Access
Chenyu Wei, Haolin Sun, Jiexuan Hu, et al.
International Immunopharmacology (2024) Vol. 133, pp. 112078-112078
Closed Access
Targeting the tumor microenvironment to improve clinical outcomes in triple negative breast cancer patients and bridge the current disparity gap
Malak Alharbi, Arya Mariam Roy, Jayasree Krishnan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Malak Alharbi, Arya Mariam Roy, Jayasree Krishnan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
